'Corporate earnings have had strong growth for the past two years in spite of the Covid-led slowdown by registering a growth of about 18% and 37% in FY21 and FY22 respectively.While the earnings growth estimates for the FY23 continue to be good at about 18-20%, there remains a concern about rise in inflation and interest rates.'

Total income in the quarter dropped to Rs 183.92 crore from Rs 295.46 crore in the year-ago period.or the full fiscal 2021-22, the company reported a consolidated net loss of Rs 429.80 crore, as against Rs 307.12 crore loss in FY21.

Considering the global macros, a strong positive catalyst may be needed to put a pause to this correction phase. Although current valuations do provide a good point to start building a strong long-term portfolio.

"The first week of the June series is expected to remain volatile as the Nifty may fail to sustain above 16,420 levels. Options data suggests that 16,000 is likely to act as an immediate support area.Once the index closes above 16,420, it can test 16,600-16,660 levels in a quick manner."

But stocks rose 6.6% this week, the first weekly gain in two months. It is certainly conceivable, although I think unlikely, that the worst of the damage is over and that the downturn of 2022 was just a flirtation with a bear market - a short affair that was never consummated. That has happened before, and fairly recently, at that

Pain in the broader market was visible clearly in the advance-decline ratio of the BSE500 index where 341 of the 501 index stocks settled lower for the week. At least 24 stocks saw double digit cuts while only eight index stocks ended the week with double-digit gains.

The standalone revenue for the quarter increased 28 per cent to Rs 17,124 crore from Rs 13,356 crore in the corresponding quarter last year.

The bullish IPO market also renewed investor interest in the market.Alongside experienced investors, first-time buyers are also venturing into the space in large numbers. The growing digitization and transforming fintech space have also accelerated the growth saga.

Softer economic growth raises risks of weaker corporate profits, in theory paving the way for softer share prices. Several Wall Street banks have in recent weeks warned that the chances of a U.S. recession are rising, along with an increased likelihood of the low-growth, high-inflation environment known as stagflation

Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period, recording an increase of 6 per cent year-on-year.For the year ended March 31, 2022, the Mumbai-based drug firm reported a PAT of Rs 994 crore, as against Rs 970 crore in FY21.